Anemia Associated with Lead Poisoning
At a Glance
Lead poisoning can cause anemia. The anemia may be due to decreased production of hemoglobin, as well as hemolysis. Signs of hemolysis may include scleral icterus and jaundice. Other symptoms associated with lead poisoning are covered in the chapter on laboratory testing for lead.
What Tests Should I Request to Confirm My Clinical Dx? In addition, what follow-up tests might be useful?
If a hemolytic anemia is in the differential, haptoglobin, lactate dehydrogenase (LDH), and bilirubin can be useful. Haptoglobin scavenges free hemoglobin and is low in hemolytic anemia.
Hemolysis may also lead to elevated LDH and bilirubin. LDH is present in red cells, and hemolysis causes release into the plasma. Bilirubin is a breakdown product of hemoglobin and becomes elevated as hemoglobin is released. Indirect hyperbilirubinemia is typically seen in hemolysis.
Review of the peripheral smear is crucial. Patients with lead poisoning will often show basophilic stippling. Microcytosis and hypochromia may be present, and reticulocyte counts may be elevated.
The direct antiglobulin test (DAT, direct Coombs test) should be negative (see chapter on laboratory testing for lead).
Are There Any Factors That Might Affect the Lab Results? In particular, does your patient take any medications - OTC drugs or Herbals - that might affect the lab results?
Haptoglobin is very sensitive but not specific for clinically significant hemolysis, as even small amounts of free hemoglobin can deplete normal levels of serum haptoglobin. It may also be decreased in liver disease. As haptoglobin is an acute phase reactant, it may be elevated in a number of diseases leading to difficulties in interpretation.
LDH is present in all tissues, including red cells, so elevations are consistent with hemolysis but very nonspecific, as any cellular damage may affect levels. As such, there are many other disorders that may cause an elevated LDH.
Other disorders may be associated with basophilic stippling.
Test Results Indicative of the Disorder
|Bilriubin, Indirect||LDH||Haptoglobin||Peripheral Smear||Lead|
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC